Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
Since December 2019, SARS-CoV-2 (COVID-19) has been a worldwide pandemic with enormous consequences for human health and the world economy. Remdesivir is the only drug in the world that has been approved for the treating of COVID-19. This drug, as well as vaccination, still has uncertain effectivene...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/3/217 |
| _version_ | 1797413697142915072 |
|---|---|
| author | Jiri Patocka Kamil Kuca Patrik Oleksak Eugenie Nepovimova Martin Valis Michal Novotny Blanka Klimova |
| author_facet | Jiri Patocka Kamil Kuca Patrik Oleksak Eugenie Nepovimova Martin Valis Michal Novotny Blanka Klimova |
| author_sort | Jiri Patocka |
| collection | DOAJ |
| description | Since December 2019, SARS-CoV-2 (COVID-19) has been a worldwide pandemic with enormous consequences for human health and the world economy. Remdesivir is the only drug in the world that has been approved for the treating of COVID-19. This drug, as well as vaccination, still has uncertain effectiveness. Drug repurposing could be a promising strategy how to find an appropriate molecule: rapamycin could be one of them. The authors performed a systematic literature review of available studies on the research describing rapamycin in association with COVID-19 infection. Only peer-reviewed English-written articles from the world’s acknowledged databases Web of Science, PubMed, Springer and Scopus were involved. Five articles were eventually included in the final analysis. The findings indicate that rapamycin seems to be a suitable candidate for drug repurposing. In addition, it may represent a better candidate for COVID-19 therapy than commonly tested antivirals. It is also likely that its efficiency will not be reduced by the high rate of viral RNA mutation. |
| first_indexed | 2024-03-09T05:21:42Z |
| format | Article |
| id | doaj.art-e42c513cd4f64053a0946438d3598ebc |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T05:21:42Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-e42c513cd4f64053a0946438d3598ebc2023-12-03T12:40:27ZengMDPI AGPharmaceuticals1424-82472021-03-0114321710.3390/ph14030217Rapamycin: Drug Repurposing in SARS-CoV-2 InfectionJiri Patocka0Kamil Kuca1Patrik Oleksak2Eugenie Nepovimova3Martin Valis4Michal Novotny5Blanka Klimova6Institute of Radiology, Toxicology and Civil Protection, Faculty of Health and Social Studies, University of South Bohemia Ceske Budejovice, 37005 Ceske Budejovice, Czech RepublicBiomedical Research Centre, University Hospital, 50003 Hradec Kralove, Czech RepublicDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech RepublicDepartment of Chemistry, Faculty of Science, University of Hradec Kralove, 50003 Hradec Kralove, Czech RepublicDepartment of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, 50003 Hradec Kralove, Czech RepublicDepartment of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, 50003 Hradec Kralove, Czech RepublicDepartment of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, 50003 Hradec Kralove, Czech RepublicSince December 2019, SARS-CoV-2 (COVID-19) has been a worldwide pandemic with enormous consequences for human health and the world economy. Remdesivir is the only drug in the world that has been approved for the treating of COVID-19. This drug, as well as vaccination, still has uncertain effectiveness. Drug repurposing could be a promising strategy how to find an appropriate molecule: rapamycin could be one of them. The authors performed a systematic literature review of available studies on the research describing rapamycin in association with COVID-19 infection. Only peer-reviewed English-written articles from the world’s acknowledged databases Web of Science, PubMed, Springer and Scopus were involved. Five articles were eventually included in the final analysis. The findings indicate that rapamycin seems to be a suitable candidate for drug repurposing. In addition, it may represent a better candidate for COVID-19 therapy than commonly tested antivirals. It is also likely that its efficiency will not be reduced by the high rate of viral RNA mutation.https://www.mdpi.com/1424-8247/14/3/217COVID-19SARS-CoV-19rapamycinsirolimusmTOR inhibitor |
| spellingShingle | Jiri Patocka Kamil Kuca Patrik Oleksak Eugenie Nepovimova Martin Valis Michal Novotny Blanka Klimova Rapamycin: Drug Repurposing in SARS-CoV-2 Infection Pharmaceuticals COVID-19 SARS-CoV-19 rapamycin sirolimus mTOR inhibitor |
| title | Rapamycin: Drug Repurposing in SARS-CoV-2 Infection |
| title_full | Rapamycin: Drug Repurposing in SARS-CoV-2 Infection |
| title_fullStr | Rapamycin: Drug Repurposing in SARS-CoV-2 Infection |
| title_full_unstemmed | Rapamycin: Drug Repurposing in SARS-CoV-2 Infection |
| title_short | Rapamycin: Drug Repurposing in SARS-CoV-2 Infection |
| title_sort | rapamycin drug repurposing in sars cov 2 infection |
| topic | COVID-19 SARS-CoV-19 rapamycin sirolimus mTOR inhibitor |
| url | https://www.mdpi.com/1424-8247/14/3/217 |
| work_keys_str_mv | AT jiripatocka rapamycindrugrepurposinginsarscov2infection AT kamilkuca rapamycindrugrepurposinginsarscov2infection AT patrikoleksak rapamycindrugrepurposinginsarscov2infection AT eugenienepovimova rapamycindrugrepurposinginsarscov2infection AT martinvalis rapamycindrugrepurposinginsarscov2infection AT michalnovotny rapamycindrugrepurposinginsarscov2infection AT blankaklimova rapamycindrugrepurposinginsarscov2infection |